H
Hossein Ardeschir Ghofrani
Researcher at University of Giessen
Publications - 576
Citations - 40678
Hossein Ardeschir Ghofrani is an academic researcher from University of Giessen. The author has contributed to research in topics: Pulmonary hypertension & Riociguat. The author has an hindex of 86, co-authored 513 publications receiving 34539 citations. Previous affiliations of Hossein Ardeschir Ghofrani include Capital Medical University & University of California, San Diego.
Papers
More filters
Journal ArticleDOI
Sildenafil citrate therapy for pulmonary arterial hypertension.
Nazzareno Galiè,Hossein Ardeschir Ghofrani,Adam Torbicki,Robyn J. Barst,Lewis J. Rubin,David B. Badesch,Thomas R. Fleming,Tamiza Parpia,Gary Burgess,Angelo Branzi,Friedrich Grimminger,Marcin Kurzyna,Gérald Simonneau +12 more
TL;DR: Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m, and the incidence of clinical worsening did not differ significantly between the patients treated with s Bildenafils and those treated with placebo.
Journal ArticleDOI
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Tomás Pulido,Igor Adzerikho,Richard N. Channick,Marion Delcroix,Nazzareno Galiè,Hossein Ardeschir Ghofrani,Pavel Jansa,Zhi-Cheng Jing,Franck-Olivier Le Brun,Sanjay Mehta,Camilla Mittelholzer,Loïc Perchenet,B.K.S. Sastry,Olivier Sitbon,Rogério Souza,Adam Torbicki,Xiaofeng Zeng,Lewis J. Rubin,Gérald Simonneau +18 more
TL;DR: Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study.
Journal ArticleDOI
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Hossein Ardeschir Ghofrani,Andrea Maria D'Armini,Friedrich Grimminger,Marius M. Hoeper,Pavel Jansa,Nick H. Kim,Eckhard Mayer,Gérald Simonneau,Martin R. Wilkins,Arno Fritsch,Dieter Neuser,Gerrit Weimann,Chen Wang +12 more
TL;DR: Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension.
Journal ArticleDOI
Reversal of experimental pulmonary hypertension by PDGF inhibition.
Ralph T. Schermuly,Eva Dony,Hossein Ardeschir Ghofrani,Soni Savai Pullamsetti,Rajkumar Savai,Markus Roth,Akylbek Sydykov,Ying Ju Lai,Norbert Weissmann,Werner Seeger,Friedrich Grimminger +10 more
TL;DR: STI571 reverses vascular remodeling and cor pulmonale in severe experimental pulmonary hypertension regardless of the initiating stimulus, and offers a unique novel approach for antire-modeling therapy in progressed pulmonary hypertension.
Journal ArticleDOI
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein Ardeschir Ghofrani,Nazzareno Galiè,Friedrich Grimminger,Ekkehard Grünig,Marc Humbert,Zhi-Cheng Jing,Anne Keogh,David Langleben,Michael Ochan Kilama,Arno Fritsch,Dieter Neuser,Lewis J. Rubin +11 more
TL;DR: Riociguat significantly improved exercise capacity and secondary efficacy end points in patients with pulmonary arterial hypertension and showed significant improvements in pulmonary vascular resistance, NT-proBNP levels, World Health Organization functional class, and time to clinical worsening.